Modified HFNC Therapy for ARF Patients Undergoing Flexible Bronchoscopy

Launched by BEIJING CHAO YANG HOSPITAL · Feb 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to provide oxygen to patients who are having difficulty breathing and need a procedure called bronchoscopy. Bronchoscopy is a procedure where a thin tube is inserted into the lungs to help doctors see and treat problems. In patients with acute respiratory failure, standard oxygen methods may not be enough, so this trial is testing a modified high-flow nasal cannula (HFNC) therapy. This new method aims to improve how well patients get oxygen during the procedure, which could lead to better health outcomes.

To participate in this trial, you need to be at least 18 years old, require a bronchoscopy, and have a specific level of oxygen in your blood (PaO2/FiO2 between 150 and 300 mmHg). If you’re interested, you’ll receive HFNC therapy, which is designed to provide higher amounts of oxygen than traditional methods. This study is currently recruiting participants of all genders, and its results will help doctors understand if this new therapy is safe and effective for managing breathing issues during bronchoscopy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old;
• • 2. Bronchoscopy is required;
• • 3. 150 mmHg ≤ PaO2/FiO2 \< 300 mmHg.
• Exclusion Criteria:
• • 1. Not tolerate HFNC oxygen therapy;
• • 2. Obstruction of nasopharynx cavity;
• • 3. Platelet\<60 × 109/L；
• • 4. Need tracheal intubation;
• • 5. The patient has received invasive ventilation.